𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gefitinib promising as second-line therapy for oesophageal cancer

✍ Scribed by Sullivan, S

Book ID
120856108
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2005
Weight
181 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Second-line treatments after first-line
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco